Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. More Details
Established dividend payer with adequate balance sheet.
Share Price & News
How has Cadila Healthcare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CADILAHC has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CADILAHC exceeded the Indian Pharmaceuticals industry which returned 50.1% over the past year.
Return vs Market: CADILAHC exceeded the Indian Market which returned 2.3% over the past year.
Price Volatility Vs. Market
How volatile is Cadila Healthcare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StHow Should Investors React To Cadila Healthcare's (NSE:CADILAHC) CEO Pay?
3 weeks ago | Simply Wall StHave Insiders Been Selling Cadila Healthcare Limited (NSE:CADILAHC) Shares?
1 month ago | Simply Wall StYou Have To Love Cadila Healthcare Limited's (NSE:CADILAHC) Dividend
Is Cadila Healthcare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CADILAHC (₹425.65) is trading above our estimate of fair value (₹209.34)
Significantly Below Fair Value: CADILAHC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CADILAHC is poor value based on its PE Ratio (32.9x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: CADILAHC is poor value based on its PE Ratio (32.9x) compared to the Indian market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: CADILAHC is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: CADILAHC is overvalued based on its PB Ratio (4.2x) compared to the IN Pharmaceuticals industry average (2.2x).
How is Cadila Healthcare forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CADILAHC's forecast earnings growth (11% per year) is above the savings rate (7.2%).
Earnings vs Market: CADILAHC's earnings (11% per year) are forecast to grow slower than the Indian market (25.5% per year).
High Growth Earnings: CADILAHC's earnings are forecast to grow, but not significantly.
Revenue vs Market: CADILAHC's revenue (7.5% per year) is forecast to grow slower than the Indian market (11.5% per year).
High Growth Revenue: CADILAHC's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CADILAHC's Return on Equity is forecast to be low in 3 years time (15.2%).
How has Cadila Healthcare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CADILAHC has high quality earnings.
Growing Profit Margin: CADILAHC's current net profit margins (9.2%) are lower than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: CADILAHC's earnings have grown by 1.6% per year over the past 5 years.
Accelerating Growth: CADILAHC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CADILAHC had negative earnings growth (-21.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).
Return on Equity
High ROE: CADILAHC's Return on Equity (11.7%) is considered low.
How is Cadila Healthcare's financial position?
Financial Position Analysis
Short Term Liabilities: CADILAHC's short term assets (₹87.2B) exceed its short term liabilities (₹82.7B).
Long Term Liabilities: CADILAHC's short term assets (₹87.2B) exceed its long term liabilities (₹37.1B).
Debt to Equity History and Analysis
Debt Level: CADILAHC's debt to equity ratio (68.2%) is considered high.
Reducing Debt: CADILAHC's debt to equity ratio has increased from 59.6% to 68.2% over the past 5 years.
Debt Coverage: CADILAHC's debt is well covered by operating cash flow (31.4%).
Interest Coverage: CADILAHC's interest payments on its debt are well covered by EBIT (8.4x coverage).
What is Cadila Healthcare current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CADILAHC's dividend (0.82%) is higher than the bottom 25% of dividend payers in the Indian market (0.56%).
High Dividend: CADILAHC's dividend (0.82%) is low compared to the top 25% of dividend payers in the Indian market (2.3%).
Stability and Growth of Payments
Stable Dividend: CADILAHC's dividends per share have been stable in the past 10 years.
Growing Dividend: CADILAHC's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27%), CADILAHC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CADILAHC's dividends in 3 years are forecast to be well covered by earnings (19.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Sharvil Patel (41 yo)
Dr. Sharvil Pankajbhai Patel has been Managing Director of Cadila Healthcare Limited since April 1, 2017 and previously served as its Joint Managing Director from March 15, 2017 to April 1, 2017. Dr. Patel ...
CEO Compensation Analysis
Compensation vs Market: Sharvil's total compensation ($USD3.39M) is above average for companies of similar size in the Indian market ($USD1.04M).
Compensation vs Earnings: Sharvil's compensation has been consistent with company performance over the past year.
|MD & Executive Director||3.5yrs||₹250.00m||0.0015% |
|COO & Executive Director||3.25yrs||₹278.94m||0.025% |
|Non-Executive Chairman||no data||₹1.70m||74.87% |
|Independent Director||4.42yrs||₹4.15m||no data|
|Non-Executive Director||23.17yrs||₹4.65m||0.0012% |
|Independent Director||1.83yrs||₹3.15m||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Non-Executive Independent Director||6.42yrs||₹4.55m||no data|
|Non-Executive Independent Director||9.42yrs||₹4.25m||0.043% |
|Member of Scientific Advisory Board||no data||no data||no data|
Experienced Board: CADILAHC's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cadila Healthcare Limited's company bio, employee growth, exchange listings and data sources
- Name: Cadila Healthcare Limited
- Ticker: CADILAHC
- Exchange: NSEI
- Founded: 1952
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹436.473b
- Shares outstanding: 1.02b
- Website: https://www.zyduscadila.com
Number of Employees
- Cadila Healthcare Limited
- Zydus Corporate Park
- Scheme No. 63
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|532321||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Apr 2000|
|CADILAHC||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Apr 2000|
Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosag ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 12:39|
|End of Day Share Price||2020/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.